# An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis

> **NCT00488631** · PHASE3 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 1228 (actual)

## Conditions studied

- Colitis, Ulcerative

## Interventions

- **BIOLOGICAL:** Placebo
- **BIOLOGICAL:** Golimumab 50 mg
- **BIOLOGICAL:** Golimumab 100 mg
- **BIOLOGICAL:** Golimumab 200 mg

## Key facts

- **NCT ID:** NCT00488631
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-09
- **Primary completion:** 2011-10
- **Final completion:** 2015-02
- **Target enrollment:** 1228 (ACTUAL)
- **Last updated:** 2016-04-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00488631

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00488631, "An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis". Retrieved via MORVS 2026-10-23 from https://api.morvs.ai/clinical/NCT00488631. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*